Though multiple lines of evidence indicate that BBB is damaged in neurodegenerative diseases, it should be noted that measurements of TfR levels in microvessels from human postmortem and 3xTg-AD mouse brains show no difference compared with the control group [43], which supports TfRs as a promising vector target for drug delivery into the brain in AD cases. The gene discussed is TFRC; the disease is neurodegenerative disease.